These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. Black PC; Brown GA; Dinney CP J Clin Oncol; 2006 Dec; 24(35):5528-35. PubMed ID: 17158538 [TBL] [Abstract][Full Text] [Related]
29. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431 [TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Andius P; Johansson SL; Holmäng S Urology; 2007 Oct; 70(4):758-62. PubMed ID: 17991551 [TBL] [Abstract][Full Text] [Related]
31. Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. Kakizoe T; Mucci LA; Albertsen PC; Droller MJ Scand J Urol Nephrol Suppl; 2008 Sep; (218):191-212. PubMed ID: 18815934 [TBL] [Abstract][Full Text] [Related]
32. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions. van der Kwast TH Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932 [TBL] [Abstract][Full Text] [Related]
33. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101 [TBL] [Abstract][Full Text] [Related]
34. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Shariat SF; Ashfaq R; Karakiewicz PI; Saeedi O; Sagalowsky AI; Lotan Y Cancer; 2007 Mar; 109(6):1106-13. PubMed ID: 17311310 [TBL] [Abstract][Full Text] [Related]
35. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118 [TBL] [Abstract][Full Text] [Related]
36. Targeting death receptors in bladder, prostate and renal cancer. O'Kane HF; Watson CJ; Johnston SR; Petak I; Watson RW; Williamson KE J Urol; 2006 Feb; 175(2):432-8. PubMed ID: 16406966 [TBL] [Abstract][Full Text] [Related]
37. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803 [TBL] [Abstract][Full Text] [Related]
38. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293 [TBL] [Abstract][Full Text] [Related]
39. Activation of RAS family genes in urothelial carcinoma. Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097 [TBL] [Abstract][Full Text] [Related]
40. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Scosyrev E; Yao J; Messing E Urology; 2009 Apr; 73(4):822-7. PubMed ID: 19193403 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]